Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II randomized, double Blind, placebo-Controlled trial evaluating the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for COVID-19 infected patients with moderate-to-severe symptoms

Next Previous
X
Search
Trial Profile

Phase II randomized, double Blind, placebo-Controlled trial evaluating the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for COVID-19 infected patients with moderate-to-severe symptoms

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Can-Fite BioPharma

    • Most Recent Events

    • 26 Nov 2021 Status changed from recruiting to discontinued, according to a Can-Fite BioPharma media release.
    • 26 Nov 2021 According to a Can-Fite Biopharma media release, with the anticipated launch of Pfizer's oral COVID-19 antiviral drug candidate, he company has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials.
    • 22 Apr 2021 According to a Can-Fite Biopharma media release, the trial has been expanded to two European countries, Romania and Bulgaria. Data are expected in Q4 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top